10:15 - 12:00

Panel Discussion: Cross-Pharma Collaborations

• Margaret Faul  Executive Director of Process Chemistry R&D, Amgen
• Chris Hill     Head of Global Chemistry, Merck Research Laboratories
• Steve King     Vice President of Development Sciences in Research Development, AbbVie
• Chris Senanayake Vice President, Chemical Development US, Boehringer-Ingelheim
• Gerry Taber    Global Technology Lead, Chemical R&D, Pfizer
• Rob Waltermire Executive Director of Late Phase Chemical Development, Bristol-Myers Squibb

Joel Hawkins, Moderator
Panel Format

• Each speaker will present a brief ~7 min introduction, making key points.
• Limited discussion following each presentation, intended for clarification.
• Questions from the audience and lively discussion encouraged after all of the introductory presentations are completed.
• In the spirit of a workshop we want to hear everyone’s ideas.
Insert slides from Panelists
Questions from the Panel

1. We are facing enormously tough problems in an increasingly difficult regulatory and commercial environment, and still have an old fashioned mind-set. This will change – it has to – but soon enough? Look at the car industry – they share motors. Samsung make a lot of parts for Apple....and so on. Why are we so special and how do we change our mind-set?
Questions from the Panel

2. Consortia take a very long time to set up legally and agree upon anything - so the question is whether there is any way we can cut through the red tape and get these collaborations running faster and more effectively?
Questions from the Panel

3. Provocatively, one could say that companies do not share their best science in consortia – since the weaker players benefit most ultimately bringing the entire effort down a notch. Unless this changes, consortia will only work for new unexplored science that nobody is any good at to start with – is there any way to change that or do we just accept it as it is?
Questions from the Panel

4. Does anyone know of an example of a consortium that delivered a top notch breakthrough science in pharma? Assuming the answer is likely no, is it fair to say that consortia are good for incremental optimization rather than breakthrough science? If the answer to the last question is no, are we happy with that and what needs to change to actually deliver a true innovation?
Questions from the Panel

5. For the correlation of Drug Substance powder properties to Drug Product performance does your company already have all the tools for measurement and modeling in place? If not, what do you see as the key gaps that a pre-competitive collaboration could address?
Questions from the Panel

6. At what levels in our organizations do these pre-competitive agreements need endorsement, and what can we do to prepare our organizations to be receptive to them?
Questions from the Panel

7. How do we continue to build trust among the players in the Pharma/vendors/academia/government space, so that precompetitive collaborations can be supported and flourish?
Questions from the Panel

8. Where does the line of pre-competitive/competitive demarcation differ across each of the contributing partners' businesses? Can we map out the common ground???
Questions from the Panel

9. Would an “Advisory Panel” with representation from the collaborating industries/academia/government help steer us in this murky area – connect with IQ?
Questions from the Panel

10. What does success look like in 5 years/10 years – are we all working towards the same vision?
Questions from the Panel

11. To impact the CMC development cycle a Precompetitive Collaboration must be disruptive. What opportunity do you consider will add the highest value in the CMC space and given the current economic climate how will you define the Value Proposition to convince your organization to invest?